Q-omics provides the consensus-scored MIR149 profile across patient tissues and cancer cell-line models. MIR149 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MIR149 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, MIR149 RNA expression shows 13,196 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, COAD, and THYM as cancer lineages where MIR149 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR149 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR149 survival associations across molecular data types. MIR149 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR149 RNA expression–survival associations across cancer types. High MIR149 expression shows unfavorable associations in LIHC, OV, THCA, KIRC and UVM, but favorable associations in BLCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MIR149 RNA expression.
This table summarizes MIR149 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR149. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR149 shows lower tumor expression in COAD and KIRC and higher tumor expression in BRCA, THCA and LUSC. The COAD box plot shows higher MIR149 RNA expression in normal versus tumor tissue (log2 FC = −0.185, t-test p = .011).
This table shows molecular features associated with MIR149 in patient tissues and cancer cell lines. In patient samples, MIR149 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
